BIOMAT Database Logo BIOMAT Database Logo

Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations. 1987

C Horne, and H Spahn, and E Mutschler, and H Knauf
Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-Universität, Frankfurt/Main, Fed. Rep. of Germany.

A method for the simultaneous determination of the cardiovascular agent verapamil and its major metabolite norverapamil in human plasma is described. Analysis is performed after alkaline extraction with n-heptane by subsequent ion-paired high performance liquid chromatographic (HPLC) separation, and direct fluorimetric measurement of both compounds (lambda maxex. = 278 nm, lambda maxem. = 320 nm). The sensitivity of the procedure (detection limit less than 1 ng/ml) is suitable for pharmacokinetic studies after therapeutic doses. The applicability of the method was tested by performing a clinical study. Plasma concentrations of two verapamil formulations for oral administration were examined. The active metabolite norverapamil was included in the investigation.

UI MeSH Term Description Entries
D008297 Male Males
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

C Horne, and H Spahn, and E Mutschler, and H Knauf
Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil.
May 1993, Arzneimittel-Forschung,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Simultaneous quantitation of verapamil, norverapamil, and N-dealkylated metabolites in human plasma following oral administration.
January 1985, Journal of chromatography,
C Horne, and H Spahn, and E Mutschler, and H Knauf
A validated method for the determination of verapamil and norverapamil in human plasma.
June 2001, Journal of pharmaceutical and biomedical analysis,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Plasma and salivary concentrations of erythromycin after administration of three different formulations.
October 1980, Postgraduate medical journal,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Verapamil concentrations in cerebrospinal fluid after oral administration.
May 1985, The New England journal of medicine,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
May 1984, Journal of pharmaceutical sciences,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Determination of chlormezanone in human plasma after administration of chlormezanone formulations.
December 1987, Arzneimittel-Forschung,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
January 1992, Pharmacological research,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
February 1995, Therapeutic drug monitoring,
C Horne, and H Spahn, and E Mutschler, and H Knauf
Stereoselective CZE method for analysis of verapamil and norverapamil in human plasma.
January 2013, Acta poloniae pharmaceutica,
Copied contents to your clipboard!